| Abstract |
[Abstract] Objective: To observe the clinical effect of iodine 131 combined with paroxetine in the treatment of patients with hyperthyroidism and mood disorders and its influence on thyroid function and anxiety and depression. Methods: From June 2018 to October 2019, 109 patients with hyperthyroidism and mood disorders in our department were selected as the research objects. 54 patients in the control group were treated with iodine 131, and 55 patients in the observation group were treated with Parfait on the basis of the control group. After Roxetine treatment, two months later, the clinical efficacy, thyroid stimulating hormone (TSH), free thyroxine (FT4), free triiodothyronine (FT3) levels, anxiety score, depression score, and symptoms were compared between the two groups of patients Self-rating scale (SCL-90), and the occurrence of adverse reactions in the two groups after medication. Results: After treatment, the total effective rate of the observation group was 92.73%, which was significantly higher than the 74.07% of the control group (P<0.05); after treatment, the levels of TSH, FT4 and FT3 in the two groups were significantly better than those before treatment (P<0.05). The levels of TSH, FT4, and FT3 in the observation group were significantly better than those in the control group (P<0.05); the SAS and SDS scores of the two groups after treatment were significantly better than those before the treatment (P<0.05), and the SAS and SDS scores in the observation group were significantly better after treatment It was better than the control group (P<0.05); the incidence of adverse reactions between the two groups was not statistically significant (P>0.05). Conclusion: Paroxetine adjuvant treatment of hyperthyroidism with mood disorders can significantly improve the clinical efficacy, improve the levels of TSH, FT4, FT3 in patients, and eliminate anxiety and depression. It is worthy of application.
|